CHMP recommends triple combination Rasitrio for Hypertension

The CHMP has adopted a positive opinion for Rasitrio (aliskiren/amlodipine/HCTZ )from Novartis for the treatment of high blood pressure.Rasitrio has been recommended as replacement therapy in patients whose blood pressure is adequately controlled on a combination of its components given concurrently at the same dose level as in the combination.Adherence to treatment is often very challenging for patients requiring three or more medications to manage their high blood pressure," said Professor Roland E. Schmieder, M.D., University Hospital of the University Erlangen-Nuremberg, Germany. "Triple combination therapy with Rasitrio provides patients with a comprehensive and convenient high blood pressure treatment in one pill.